Antibodies Production, Polyclonal Antibody, Monoclonal Antibody, Cancer Monoclonal Antibody
Table Of Contents
Antibodies Industry Data Book | Forecast 2030
Antibodies Industry Data Book – Antibodies Production, Polyclonal Antibody, Monoclonal Antibody, Cancer Monoclonal Antibody, Research Antibody, Custom Antibody, Mammalian IgG Polyclonal Antibody Market
Grand View Research’s antibodies industry data book is a collection of market sizing & forecast insights, market dynamics & trends, opportunity assessment, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analysis studies. Within the purview of the data book, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research. The following data points will be included in the final product offering in Seven reports and one sector report overview.
Access the Global Antibodies Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies
Antibody Production Market Report Highlights
Based on product, the consumables segment dominated in terms of the revenue share of 55.93% in 2022. This is attributed to growing demand for antibodies for study, diagnostics, and therapeutics, which has steered to a corresponding rise in the demand for consumables
Based on process, the downstream segment dominated in terms of the revenue share of 67.04% in 2022 owing to the various technological advancements supporting the downstream process to maintain efficiency, thus, fueling innovations in bio-manufacturing, and hence, increasing the demand for the process in the antibody production market
In 2022, North America dominated with a revenue share of 38.29%, owing to the rising investments in drug discovery, growing developments in biopharmaceutical research, and the presence of major key players are anticipated to drive the growth of the antibody production market in this region
Order your copy of the Free Sample of “Antibodies Industry Data Book – Antibodies Production, Polyclonal Antibody, Monoclonal Antibody, Cancer Monoclonal Antibody, Research Antibody, Custom Antibody, Mammalian IgG Polyclonal Antibody Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 – 2030”, Data Book published by Grand View Research
Polyclonal Antibodies Market Report Highlights
Based on the product, the secondary antibodies segment dominated in terms of the revenue share of 56.14% in 2022, owing to the high sensitivity and enhanced signal amplification quality, thus increasing the demand in the industry
Based on end-user, the hospital & diagnostic centers segment dominates in terms of the revenue share of 59.81% in 2022. This is attributed to the increasing demand for pAbs-based assays in diagnostic centers and the rising prevalence of chronic & infectious diseases
Based on application, the diagnostics segment dominated in terms of the revenue share of 59.81% in 2022. Due to the ability of pAbs to recognize the epitopes of targeted molecules, it is regarded as the optimum reagent in hemagglutination assays and diagnostics. Thus, increasing the demand for diagnostics in the application segment
Monoclonal Antibodies Market Report Highlights
By source type, the human mAbs segment held the largest share of 54.3% in 2022 due to the low immunogenicity offered and increasing cancer treatment applications of these antibodies
In vitro production type held a dominating share of 76.9% in 2022 due to the low contamination levels offered by the technique and the availability of advanced bio-manufacturing capabilities
The oncology segment dominated the market in 2022 due to the rising number of approvals for mAb cancer therapeutics and increasing scientific and patient awareness about such therapies
Hospitals accounted for the largest share of the end-use segment in 2022 due to the widespread use of mAbs for cancer treatment in hospitals and increasing healthcare expenditure favoring the adoption of such therapeutics
Cancer Monoclonal Antibodies Market Report Highlights
By type, the humanized segment held a larger share of the market in 2021 owing to factors such as, low cost, availability, and quick production time for mouse monoclonal antibodies. However, the human segment is expected to hold the highest CAGR during the forecast period due to an increase in the number of product approvals and product launches
The blood cancer application segment held a significant revenue share in 2021 owing to an increase in the prevalence of hematological disorders along with a robust pipeline. In addition, the lung cancer segment is poised to expand at the highest CAGR during the forecast period
Research Antibodies Market Report Highlights
In 2022, the primary product segment held the largest revenue share due to the higher specificity and direct detection capabilities offered by the antibodies
By type, monoclonal antibodies captured a substantial share in 2022 due to the increase in COVID-19-related research activities involving the use of such antibodies
The western blotting technology segment held a dominant share of over 29.57% in 2022 because of the increasing investments in R&D activities by several biotechnology and pharmaceutical companies and the rapidly growing applications of antibodies in western blots created for proteomic studies
Custom Antibody Market Report Highlights
By type, the monoclonal antibody segment is considered to be a relatively more mature and dominant segment than polyclonal in 2022. The increasing R&D investment by companies is expected to support the growth of the custom antibody market
By service, the antibody development segment captured the majority of the custom antibody market share in 2022. The number and type of players in this service segment are greater than antibody production and fragmentation, which is contributing to the growth
By source, the mice segment is estimated to be the fastest-growing during the forecast period. This is because mice are widely available lab animals and can be easily used for custom antibody production
